Caffeine and progression of parkinson disease

David K. Simon, Christopher J. Swearingen, Robert A. Hauser, Joel M. Trugman, Michael J. Aminoff, Carlos Singer, Daniel Truong, Barbara C. Tilley

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objective: Caffeine use is negatively associated with the risk of developing Parkinson disease (PD) and is protective in animal models of PD, but the relationship between caffeine intake and rate of progression of PD is unknown. We assessed this relationship using data from 2 recent clinical trials of PD. Methods: Data were ascertained from 2 recent 1-year clinical trials that together included 413 early PD subjects who did not require symptomatic therapy at the time of study entry. Exploratory analyses compared caffeine intake with rate of progression of PD, as measured by either the likelihood of progression to the point of requiring symptomatic therapy or by change in the total Unified Parkinson Disease Rating Scale score. Results: Rate of progression of PD did not differ significantly between those in the highest and lowest quartiles for caffeine use for either of the primary measures or for secondary analyses of changes in scores on the motor or activities of daily living subsections of the Unified Parkinson Disease Rating Scale. Other secondary analyses yielded variable results. Conclusions: These data do not reveal a consistent relationship between caffeine intake and rate of progression of PD by these measures, although a larger study is required for sufficient power to more fully assess this relationship.

Original languageEnglish
Pages (from-to)189-196
Number of pages8
JournalClinical Neuropharmacology
Volume31
Issue number4
DOIs
StatePublished - Jul 1 2008

Fingerprint

Caffeine
Parkinson Disease
Clinical Trials
Time and Motion Studies
Activities of Daily Living
Motor Activity
Animal Models
Therapeutics

Keywords

  • Adenosine A2A receptor
  • Coffee
  • Disease modifying
  • Neuroprotection

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Clinical Neurology

Cite this

Simon, D. K., Swearingen, C. J., Hauser, R. A., Trugman, J. M., Aminoff, M. J., Singer, C., ... Tilley, B. C. (2008). Caffeine and progression of parkinson disease. Clinical Neuropharmacology, 31(4), 189-196. https://doi.org/10.1097/WNF.0b013e31815a3f03

Caffeine and progression of parkinson disease. / Simon, David K.; Swearingen, Christopher J.; Hauser, Robert A.; Trugman, Joel M.; Aminoff, Michael J.; Singer, Carlos; Truong, Daniel; Tilley, Barbara C.

In: Clinical Neuropharmacology, Vol. 31, No. 4, 01.07.2008, p. 189-196.

Research output: Contribution to journalArticle

Simon, DK, Swearingen, CJ, Hauser, RA, Trugman, JM, Aminoff, MJ, Singer, C, Truong, D & Tilley, BC 2008, 'Caffeine and progression of parkinson disease', Clinical Neuropharmacology, vol. 31, no. 4, pp. 189-196. https://doi.org/10.1097/WNF.0b013e31815a3f03
Simon DK, Swearingen CJ, Hauser RA, Trugman JM, Aminoff MJ, Singer C et al. Caffeine and progression of parkinson disease. Clinical Neuropharmacology. 2008 Jul 1;31(4):189-196. https://doi.org/10.1097/WNF.0b013e31815a3f03
Simon, David K. ; Swearingen, Christopher J. ; Hauser, Robert A. ; Trugman, Joel M. ; Aminoff, Michael J. ; Singer, Carlos ; Truong, Daniel ; Tilley, Barbara C. / Caffeine and progression of parkinson disease. In: Clinical Neuropharmacology. 2008 ; Vol. 31, No. 4. pp. 189-196.
@article{861790200e134f979aa238ce9b166d0b,
title = "Caffeine and progression of parkinson disease",
abstract = "Objective: Caffeine use is negatively associated with the risk of developing Parkinson disease (PD) and is protective in animal models of PD, but the relationship between caffeine intake and rate of progression of PD is unknown. We assessed this relationship using data from 2 recent clinical trials of PD. Methods: Data were ascertained from 2 recent 1-year clinical trials that together included 413 early PD subjects who did not require symptomatic therapy at the time of study entry. Exploratory analyses compared caffeine intake with rate of progression of PD, as measured by either the likelihood of progression to the point of requiring symptomatic therapy or by change in the total Unified Parkinson Disease Rating Scale score. Results: Rate of progression of PD did not differ significantly between those in the highest and lowest quartiles for caffeine use for either of the primary measures or for secondary analyses of changes in scores on the motor or activities of daily living subsections of the Unified Parkinson Disease Rating Scale. Other secondary analyses yielded variable results. Conclusions: These data do not reveal a consistent relationship between caffeine intake and rate of progression of PD by these measures, although a larger study is required for sufficient power to more fully assess this relationship.",
keywords = "Adenosine A2A receptor, Coffee, Disease modifying, Neuroprotection",
author = "Simon, {David K.} and Swearingen, {Christopher J.} and Hauser, {Robert A.} and Trugman, {Joel M.} and Aminoff, {Michael J.} and Carlos Singer and Daniel Truong and Tilley, {Barbara C.}",
year = "2008",
month = "7",
day = "1",
doi = "10.1097/WNF.0b013e31815a3f03",
language = "English",
volume = "31",
pages = "189--196",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Caffeine and progression of parkinson disease

AU - Simon, David K.

AU - Swearingen, Christopher J.

AU - Hauser, Robert A.

AU - Trugman, Joel M.

AU - Aminoff, Michael J.

AU - Singer, Carlos

AU - Truong, Daniel

AU - Tilley, Barbara C.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Objective: Caffeine use is negatively associated with the risk of developing Parkinson disease (PD) and is protective in animal models of PD, but the relationship between caffeine intake and rate of progression of PD is unknown. We assessed this relationship using data from 2 recent clinical trials of PD. Methods: Data were ascertained from 2 recent 1-year clinical trials that together included 413 early PD subjects who did not require symptomatic therapy at the time of study entry. Exploratory analyses compared caffeine intake with rate of progression of PD, as measured by either the likelihood of progression to the point of requiring symptomatic therapy or by change in the total Unified Parkinson Disease Rating Scale score. Results: Rate of progression of PD did not differ significantly between those in the highest and lowest quartiles for caffeine use for either of the primary measures or for secondary analyses of changes in scores on the motor or activities of daily living subsections of the Unified Parkinson Disease Rating Scale. Other secondary analyses yielded variable results. Conclusions: These data do not reveal a consistent relationship between caffeine intake and rate of progression of PD by these measures, although a larger study is required for sufficient power to more fully assess this relationship.

AB - Objective: Caffeine use is negatively associated with the risk of developing Parkinson disease (PD) and is protective in animal models of PD, but the relationship between caffeine intake and rate of progression of PD is unknown. We assessed this relationship using data from 2 recent clinical trials of PD. Methods: Data were ascertained from 2 recent 1-year clinical trials that together included 413 early PD subjects who did not require symptomatic therapy at the time of study entry. Exploratory analyses compared caffeine intake with rate of progression of PD, as measured by either the likelihood of progression to the point of requiring symptomatic therapy or by change in the total Unified Parkinson Disease Rating Scale score. Results: Rate of progression of PD did not differ significantly between those in the highest and lowest quartiles for caffeine use for either of the primary measures or for secondary analyses of changes in scores on the motor or activities of daily living subsections of the Unified Parkinson Disease Rating Scale. Other secondary analyses yielded variable results. Conclusions: These data do not reveal a consistent relationship between caffeine intake and rate of progression of PD by these measures, although a larger study is required for sufficient power to more fully assess this relationship.

KW - Adenosine A2A receptor

KW - Coffee

KW - Disease modifying

KW - Neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=53449095363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53449095363&partnerID=8YFLogxK

U2 - 10.1097/WNF.0b013e31815a3f03

DO - 10.1097/WNF.0b013e31815a3f03

M3 - Article

VL - 31

SP - 189

EP - 196

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 4

ER -